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Context: There are few studies on patients transitioning from denosumab to bisphosphonates.
Objective: To investigate patient characteristics and changes in bone mineral density (BMD) 
after transitioning from denosumab to alendronate.
Design: Randomized, open-label, 2-year crossover Denosumab Adherence Preference 
Satisfaction (DAPS) study (NCT00518531).
Setting: 25 study centers in the US and Canada.
Patients: Treatment-naïve postmenopausal women with BMD T-scores from −2.0 to −4.0.
Interventions: This post hoc analysis evaluated women randomized to subcutaneous 
denosumab 60 mg every 6 months in year 1 followed by once-weekly oral alendronate 70 mg in 
year 2.
Main Outcome Measure: A 3% BMD threshold identified participants who lost, maintained, or 
gained BMD in year 2 on alendronate.
Results: Of 126 participants randomized to denosumab, 115 (91%) transitioned to alendronate in 
year 2. BMD increased by 3% to 6% with denosumab in year 1 and by 0% to 1% with alendronate 
in year 2. After transitioning to alendronate, most participants maintained or increased BMD; 
15.9%, 7.6%, and 21.7% lost BMD at the lumbar spine, total hip, and femoral neck, respectively. 
Few participants fell below their pretreatment baseline BMD value; this occurred most often in 
those who lost BMD in year 2. Women who lost BMD with alendronate in year 2 also showed a 
greater percent change in BMD with denosumab in year 1. The BMD change in year 2 was similar 
regardless of baseline characteristics or adherence to oral alendronate.
Conclusion: Alendronate can effectively maintain the BMD gains accrued after 1 year of denosumab 
in most patients, regardless of baseline characteristics. (J Clin Endocrinol Metab 105: e255–e264, 2020)
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Postmenopausal osteoporosis is a chronic disease associated with age-related declines in bone mass, 
changes in bone microarchitecture, and skeletal fra-
gility. These changes place postmenopausal women at 
increased risk of fragility fractures, which are linked 
to significant morbidity, economic cost, and nega-
tive impact on health-related quality of life (1–4). 
Antiresorptive therapies, including bisphosphonates and 
denosumab, have been demonstrated to reduce fracture 
incidence and increase bone mineral density (BMD) in 
postmenopausal women with osteoporosis (5–9), al-
though the optimal duration and sequencing of avail-
able treatments remain poorly understood. Whereas 
bisphosphonates bind to bone mineral and become in-
corporated into bone matrix, denosumab, a monoclonal 
antibody targeting receptor activator of nuclear factor 
kappa-B ligand (RANKL), is a reversible therapy. There 
is a rebound in bone turnover after treatment cessation, 
leading to loss of the bone density gained on treatment 
and loss of vertebral fracture protection (10–12). If 
denosumab is discontinued, follow-on therapy with a 
bisphosphonate has been recommended to prevent re-
versible bone loss (13, 14), although limited data are 
available on patients transitioning from denosumab to 
bisphosphonates, such as alendronate.
The Denosumab Adherence Preference Satisfaction 
(DAPS) study was a 24-month study designed to com-
pare adherence to denosumab with alendronate over 
12 months in postmenopausal women with low BMD. 
Participants were randomized to receive denosumab or 
alendronate for the first year, after which they crossed 
over to receive the other treatment for the second 
year. We previously reported that the primary efficacy 
endpoints of adherence, preference, and satisfaction 
favored injectable denosumab over oral alendronate 
and that alendronate could maintain the gains in BMD 
achieved with 1 year of denosumab treatment (15, 16). 
Here we perform a descriptive subanalysis of partici-
pants randomized to the denosumab/alendronate se-




The DAPS study (NCT00518531) was a 24-month, 
multicenter, randomized, open-label, crossover study con-
ducted at 20 centers in the US and 5 centers in Canada, from 
October 2007 to July 2010. Study details have been previously 
described (15, 16). Briefly, participants were randomized 1:1 
to receive 1 of 2 treatment sequences: denosumab followed by 
alendronate or alendronate followed by denosumab. The cur-
rent analysis focused on the denosumab/alendronate sequence, 
in which subjects received subcutaneous denosumab, 60 mg 
every 6 months, in the first year and then crossed over to oral 
alendronate, 70 mg once weekly, in the second year. All parti-
cipants received daily supplementation of calcium (1000 mg) 
and vitamin D (at least 400 IU). Women who withdrew from 
treatment during the first year but wished to remain in the 
study were allowed to crossover early to the second year of 
treatment.
Eligibility criteria
Enrolled participants were ambulatory postmenopausal 
women aged 55 years or older with baseline BMD T-scores 
from −4.0 to −2.0 at the lumbar spine (LS), total hip (TH), 
or femoral neck (FN), as measured using dual-energy x-ray 
absorptiometry (DXA). Patients were excluded if they had 
received prior bisphosphonate or denosumab treatment or 
bone-acting drugs, including glucocorticoids. Additional ex-
clusion criteria included hyper/hypocalcemia, vitamin D de-
ficiency (< 20  ng/mL [49.9  nmol/L]), or contraindications 
to alendronate treatment. Written informed consent was 
obtained from each participant, and this study was conducted 
in accordance with the principles set out in the Declaration 
of Helsinki and was formally approved by the appropriate in-
stitutional review board, ethical review committee, or equiva-
lent at each study site.
Outcome measures
BMD at the LS, TH, and FN was measured by DXA at 
baseline (day 1 visit) and at months 12 and 24 of the treat-
ment period. DXA scans were performed at the local study 
sites, and the same DXA machine was used for all study pro-
cedures for a particular participant. Bone turnover markers 
(BTMs), including fasting serum C-telopeptide (CTX-1) and 
N-terminal propeptide type I  procollagen (P1NP), were as-
sessed at baseline and months 12, 18, and 24 of treatment. 
Adherence to oral alendronate was defined as a composite 
endpoint of A) taking ≥ 80% of weekly alendronate tablets 
(overall treatment compliance) and at least 2 tablets in the last 
month (treatment persistence), as monitored using Medication 
Event Monitoring System (MEMS) technology, and B) com-
pleting the relevant treatment period. We evaluated partici-
pant characteristics including baseline age, history of fracture, 
baseline BMD, change in BMD at months 12 and 24, change 
in BTM at months 12 and 24, and adherence to alendronate.
Statistical analyses
BMD and BTM values were summarized using descrip-
tive statistics and plotted as the mean with 95% confidence 
interval (CI) and median with interquartile range (IQR), re-
spectively. BMD change during the study period was also 
plotted at the level of individual participants. Descriptive ana-
lysis was performed to evaluate baseline and month 12 and 
24 characteristics in groups of participants that lost, main-
tained, or gained BMD after transitioning from denosumab 
to alendronate in year 2, defined using a 3% BMD least sig-
nificant change threshold. The 3% threshold was selected 
according to DXA scanner precision of approximately 1% 
corresponding to an approximate least significant change in 
BMD of 3%, as applied previously in responder analyses of 
drugs used to treat osteoporosis or increase BMD (17–21). For 
LS BMD assessment, participants were excluded if there were 
fewer than 4 evaluable vertebrae. A change in BMD ≤ −3% 
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indicated lost BMD, change from > −3% to < 3% indicated 
maintained BMD, and change ≥ 3% indicated gained BMD. 
This grouping was applied separately for each skeletal site. All 
analyses were descriptive in nature. A summary of incidence of 
adverse events was generated for each treatment year.
Results
Participant characteristics
The DAPS study enrolled 250 participants. Of 126 
women randomized to the denosumab/alendronate se-
quence, 114 (90.5%) completed denosumab treatment 
in year 1 and 115 (91%) transitioned to alendronate 
at month 12, including 3 who crossed over early. 
Alendronate treatment in year 2 was completed by 95 
participants (82.6%). Most common reasons for dis-
continuation before completion of treatment included 
withdrawn consent (6 participants [4.8%] in year 1; 8 
[7.0%] in year 2), lost to follow-up (3 [2.4%] in year 
1; 0 [0.0%] in year 2), and adverse events (0 [0.0%] in 
year 1; 7 [6.1%] in year 2) (Table 1). Characteristics of 
the 126 participants initiating denosumab treatment in 
year 1 and the 115 participants initiating alendronate 
treatment in year 2 are shown in Table 2. At baseline, 
participants had a mean age of 65 years and mean BMD 
T-scores of −2.0, −1.6, and −2.0 at the LS, TH, and FN, 
respectively. Prior osteoporotic fracture was reported 
for 37.3% of participants at baseline. Similar charac-
teristics were observed for the participants who transi-
tioned to alendronate at month 12.
Change in BMD and BTM with denosumab in year 
1 and alendronate in year 2
With denosumab treatment in year 1, the mean 
percent change in BMD from baseline to month 12 
was 5.4%, 3.1%, and 2.7% for the LS, TH, and FN, 
respectively. After transitioning to alendronate in year 
2, the mean percent change in BMD from month 12 to 
month 24 was 0.5%, 0.5%, and −0.2% at the LS, TH, 
and FN, respectively. Evaluating the entire study period, 
participants showed an average gain in BMD above 
baseline of 5.9%, 3.6%, and 2.5% at the LS, TH, and 
FN, respectively (Fig.  1). The median percent change 
in CTX-1 from baseline to month 12, month 18, and 
month 24 was −69.1%, −64.7%, and −54.8%, respect-
ively. The median percent change in P1NP from baseline 
to month 12, month 18, and month 24 was −67.7%, 
−57.0%, and −53.1%, respectively (Fig. 2).
Participants grouped into those who lost, 
maintained, or gained BMD in year 2
Fig. 3 shows BMD responses for individual partici-
pants throughout the study for the groups that lost, main-
tained, and gained BMD during year 2 on alendronate. 
Of the 82 participants with BMD measurements avail-
able at the LS, 13 (15.9%) lost BMD, 52 (63.4%) main-
tained BMD, and 17 (20.7%) gained BMD at this site. 
Of the 92 participants with BMD measurements avail-
able at the TH and FN, 7 (7.6%) lost BMD, 75 (81.5%) 
maintained BMD, and 10 (10.9%) gained BMD at the 
TH, and 20 (21.7%) lost BMD, 56 (60.9%) maintained 
BMD, and 16 (17.4%) gained BMD at the FN (Table 3). 
Of the 82 participants with BMD measurements avail-
able at the LS, TH, and FN, only 1 participant (1.2%) 
lost BMD at all 3 sites.
Participant characteristics and BMD change in 
year 2
The BMD change in year 2 was similar regardless 
of baseline characteristics such as age, BMD T-score, 
baseline levels of BTMs, and history of fracture 
(Table 3). For all skeletal sites, subjects who lost BMD 
Table 1. Numbers of Participants Completing Each Treatment Period and Reasons for Study Discontinuation
Denosumab/Alendronate Sequence
 Denosumab Year 1 (N = 126) Alendronate Year 2 (N = 115)
Completed treatment period, n (%) 114 (90.5) 95 (82.6)
Discontinued before completing treatment period, n (%) 12 (9.5) 20 (17.4)
 Early crossover 3 (2.4) N/A
  Adverse event 2 (1.6) N/A
  Administrative decision 1 (0.8) N/A
 Early termination 9 (7.1) 20 (17.4)
  Consent withdrawn 6 (4.8) 8 (7.0)
  Lost to follow-up 3 (2.4) 0 (0.0)
  Adverse event 0 (0.0) 7 (6.1)
  Complete out of scheduled visit window 0 (0.0) 2 (1.7)
  Noncompliance 0 (0.0) 2 (1.7)
  Protocol-specified criteria 0 (0.0) 1 (0.9)
N = number of participants randomized (year 1) or crossed over (year 2); n = number of participants with the characteristic of interest; N/A = not 
applicable.
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with alendronate in year 2 had shown a greater per-
cent change in BMD with denosumab in year 1 (Fig. 3, 
Table  3). At the LS, participants who lost BMD in 
year 2 had gained an average of 7.1% BMD in year 1, 
while those who gained BMD in year 2 had gained an 
average of 3.1% BMD in year 1, and a similar differ-
ence was observed at the TH (6.2% vs 2.8%). At the 
FN, participants who lost BMD in year 2 had gained 
an average of 7.0% BMD in year 1, while those who 
gained BMD in year 2 had gained an average of 0.6% 
BMD in year 1. BMD did not fall below pretreatment 
baseline in the majority of participants and was ob-
served most often in participants who lost BMD with 
alendronate. Among participants who lost BMD in 
year 2 at a given skeletal site, 23.1% fell below their 
baseline BMD value at the LS, 28.6% fell below their 
baseline value at the TH, and 50.0% fell below their 
baseline value at the FN.
While adherence to oral alendronate in year 2 was 
lower than adherence to denosumab in year 1 (16), there 
was no numeric trend between alendronate adherence 
and the BMD response in year 2 (Table 3). Compliance, 
defined as the percentage of provided alendronate tab-
lets taken, was also investigated in terms of the BMD 
change in year 2 using quartiles of compliance, and 
there were no differences in the percent change in BMD 
in year 2 among the 4 compliance subgroups (data not 
shown).
Adverse event summary
Safety analysis was performed for 125 participants 
who received at least 1 dose of denosumab in year 1 
and 110 participants who received at least 1 dose of 
alendronate in year 2 (Table  4). The adverse event 
profiles were similar between treatment periods, with 
74.4% and 61.8% of participants experiencing ad-
verse events during denosumab and alendronate treat-
ment, respectively. The most frequent adverse events 
(denosumab year 1, alendronate year 2) included arth-
ralgia (8.8%, 6.4%), pain in extremity (7.2%, 3.6%), 
back pain (4.0%, 2.7%), and cough (4.0%, 4.5%). 
Adverse events of fracture were experienced by 1 par-
ticipant during year 1 and 1 participant during year 2; 
both fracture events were classified as osteoporotic and 
Table 2. Participant Characteristics at Study Baseline
Denosumab/Alendronate Sequence
 Denosumab Year 1 (N = 126) Alendronate Year 2 (N = 115)
Race/ethnicity—white, n (%) 115 (91) 107 (93)
Age, mean (SD), years 65.1 (7.6) 65.1 (7.4)
Years since menopause, mean (SD) 18.2 (11.4) 17.9 (10.9)
BMD T-score at the start of each year, mean (SD)   
 Lumbar spine –2.04 (1.16) –1.61 (1.29)
 Total hip –1.60 (0.74) –1.38 (0.74)
 Femoral neck  –2.01 (0.55) –1.84 (0.6)
Prior osteoporotic fracture, n (%) 47 (37.3) 41 (35.7)
N = number of participants randomized (year 1) or crossed over (year 2); n = number of participants with the characteristic of interest.
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Figure 1. BMD percentage change from baseline with denosumab in year 1 and alendronate in year 2. Data show mean and 95% confidence 
interval. n = number of participants with measurements at baseline and month 12 (DMAb) or month 24 (ALN). Abbreviations: ALN, alendronate; 
BMD, bone mineral density; DMAb, denosumab.
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nonvertebral. No deaths, osteonecrosis of the jaw, or 
atypical femoral fractures were reported.
Discussion
Transitioning to alendronate was generally effective at 
preserving the gain in BMD and suppression of BTMs 
achieved with 1 year of denosumab treatment. Among 
the minority of participants who lost BMD at the LS, 
TH, or FN after transitioning to alendronate, few fell 
below their pretreatment baseline BMD value, and only 
1 participant lost BMD at all skeletal sites. Larger BMD 
increases in year 1 on denosumab were observed for par-
ticipants who lost BMD in year 2 on alendronate, while 
other participant characteristics showed no numeric 
trend with the BMD response in year 2 on alendronate. 
These findings demonstrate that most women receive 
benefit from oral bisphosphonate therapy following 
denosumab cessation.
In the pivotal phase 3, randomized FREEDOM trial 
and open-label extension, treatment with denosumab 
for up to 10 years was associated with a continued in-
crease in BMD, sustained reduction in BTMs, and low 
incidence of fractures, and was generally well tolerated 
(9). In head-to-head studies, denosumab treatment led 
to larger increases in BMD and greater reductions in 
BTMs compared with alendronate (22, 23), which is in 
agreement with the results presented here. However, be-
cause denosumab is a reversible inhibitor of RANKL, 
denosumab’s effects on bone turnover are reversible with 
discontinuation, and cessation of denosumab has been 
associated with rapid loss of vertebral fracture protec-
tion, including multiple vertebral fracture (24). Thus, al-
though denosumab treatment can produce large gains in 
BMD and significant suppression of BTMs, these effects 
do not protect patients when therapy is discontinued. 
For this reason, the use of a “drug holiday” in patients 
receiving denosumab is not recommended (25). The de-
cision to discontinue denosumab treatment should be ac-
companied by careful monitoring and use of a follow-on 
antiremodeling agent.
Limited data are available regarding the optimal post-
denosumab bisphosphonate treatment regimen (26). In 
a small case series evaluating women followed for up to 
2 years after the FRAME trial, zoledronic acid (n = 11) 
infusion after denosumab discontinuation showed 73% 
to 87% preservation of the gains in BMD at the TH or LS 
after 1 year, with minimal further BMD loss at any skel-
etal site in year 2; participants given risedronate (n = 5) 
showed only partial preservation of BMD (41%–64%) 
(13, 27). These findings are somewhat inconsistent with 
a previous, smaller case series showing only minimal ef-
ficacy to preserve BMD after denosumab treatment ces-
sation (28). This difference in outcome may be related to 
the inclusion of participants with different ages, previous 
osteoporosis treatments, and durations of denosumab 
treatment, and it should be noted that intravenous 
zoledronic acid was administered 6 or 8  months after 
the last denosumab injection. In the current analysis, 
which included a larger number of participants , 1 year 
of alendronate treatment following 1 year of denosumab 
led to maintained or increased BMD at the TH or LS in 
84% to 92% of participants. These findings demonstrate 
the potential for bisphosphonate treatment to prevent re-
versible bone loss in patients who discontinue denosumab 
treatment and may suggest that oral alendronate helps 
maintain BMD in the period immediately following 
denosumab discontinuation when the effects of treat-
ment on bone turnover have dissipated. Ongoing ran-
domized clinical trials evaluating bisphosphonate use 
after denosumab discontinuation should provide clarity 
on the optimal treatment regimen (29, 30).
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Figure 2. BTM percentage change from baseline with denosumab in year 1 and alendronate in year 2. Data show mean and interquartile range. n 
= number of participants with measurements at baseline and month 12 (DMAb) or month 24 (ALN). Abbreviations: ALN, alendronate; BTM, bone 
turnover marker; CTX-1, serum C-telopeptide; DMAb, denosumab; P1NP, N-terminal propeptide type I procollagen. aAt month 18, n = 60.
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Although the majority of participants maintained 
or gained BMD after transitioning from denosumab 
to alendronate in the current analysis, 15.9%, 7.6%, 
and 21.7% lost BMD at the LS, TH, and FN, respect-
ively, with only 1 participant losing BMD at all sites. 
These differences between sites in the response to treat-
ment may be due to differences in the proportions of 
cortical versus trabecular bone as well as load-bearing 
parameters. Also, degenerative artifact is likely to have 
a greater impact on BMD at the LS compared with 
TH. In general, cortical bone may respond less rap-
idly to antiresorptive therapies compared with tra-
becular bone, as cortical bone has less surface area per 
unit volume of mineralized bone matrix upon which 
bisphosphonates can be adsorbed (31). Specifically, 
denosumab is likely to have superior effects on cortical 
bone as compared with alendronate. In a head-to-head 
study using high-resolution peripheral computed tom-
ography (HR-pQCT), there was greater reduction in 
cortical porosity at the radius and tibia in patients re-
ceiving denosumab compared with alendronate (32). 
Supportive data using another technology to measure 
cortical porosity indicate the efficacy of denosumab 
in reducing cortical porosity at the hip, a load-bearing 
site (33). Although the FN is included in the TH region 
of interest, the FN comprises a much smaller region 
and provides a less precise measurement than the TH, 
























































































































































Figure 3. Individual participant BMD changes for groups that lost, maintained, or gained BMD in year 2 on alendronate. Abbreviation: BMD, bone 
mineral density.
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individual patients. Together, these differences can lead 
to variability in the clinical response to osteoporosis 
therapies.
The current analysis sought to better understand 
patient characteristics linked to loss of BMD after 
transitioning from denosumab to alendronate treat-
ment, and our results identified the change in BMD 
with denosumab treatment from baseline to month 
12. Specifically, the BMD gain in year 1 on denosumab 
was numerically higher in individuals who lost BMD 
in year 2 on alendronate than in those who maintained 
or gained BMD in year 2. This result may be attrib-
utable to “regression to the mean,” a characteristic of 
imprecision of measurement. Bone remodeling differs 
between individuals and is influenced by a variety of 
factors (34, 35). Closure of the remodeling space with 
antiresorptive treatment in high remodelers might 
produce greater gains in BMD with treatment. In these 
individuals, subsequent discontinuation of reversible 
treatment may result in resumption of the same level 
of remodeling, which may not be fully inhibited with a 
bisphosphonate. However, alendronate treatment was 
able to maintain BMD above the pretreatment base-
line level in the majority of women who lost BMD in 
year 2.
No other baseline or year 1 participant character-
istics could consistently identify participants who lost 
BMD after transitioning to alendronate treatment 
in this analysis. This finding suggests that all pa-
tients, regardless of baseline characteristics and frac-
ture history, may benefit from follow-on therapy with 
bisphosphonates after discontinuation of denosumab. 
We did not observe a meaningful effect of adherence 
to oral alendronate treatment on the change in BMD in 
year 2 after denosumab discontinuation. However, this 
may be the result of the overall good adherence in our 
clinical trial patient population, as compared to clinical 
practice where adherence can be low. Thus, it is likely 
that the low rate of nonadherence did not allow us to 
detect an effect of nonadherence on BMD decline in our 
patient population. Our findings also stress the import-
ance of BMD monitoring while on treatment to identify 
those at greatest risk for fracture, as those patients with 
the largest increase in BMD with denosumab might also 
be the most vulnerable to BMD loss while receiving 
alendronate. Unfortunately, in clinical practice, most 
patients who discontinue denosumab treatment do not 
receive any osteoporosis treatment in the year following 
discontinuation; moreover, approximately half of those 
who begin a prescription medication for osteoporosis 
after denosumab cessation stop the therapy in the sub-
sequent year (11).
Several limitations of this analysis should be con-
sidered. First, denosumab was only administered 
for 1  year before transition to alendronate. With 
longer-term denosumab treatment, there will be con-
tinued gains in BMD and the potential for greater bone 
loss after treatment is stopped, and it could be more 
difficult to preserve bone mass when transitioning to 
bisphosphonates. Determining the optimal timing, 
dose, and bisphosphonate medication to administer 
after denosumab cessation warrants further study. 
Second, this post hoc analysis had a modest sample 
size, particularly for the analysis of participants divided 
into BMD response groups (ie, lost, maintained, and 
gained). However, the current sample size is larger than 
that reported in other ad-hoc case series investigating 
denosumab discontinuation and bisphosphonate 
follow-on therapy. Third, the analysis was not powered 
to detect statistical relationships between participant 
characteristics and their BMD response in year 2, and all 
analyses were descriptive in nature. Fourth, the effect-
iveness of alendronate to maintain BMD in this study 
may have been unrealistically high, given the difficulties 
with compliance and dosing faced in clinical practice 
(36). Finally, DXA assessment for this study was not 
centralized; therefore, BMD results may vary by center.
Denosumab treatment increased BMD at all skel-
etal sites examined, and the gains in BMD achieved 
with denosumab were maintained in the majority of 
participants after transitioning to alendronate. Among 





Year 1  
(N = 125)
Alendronate  
Year 2  
(N = 110)
Adverse events, n (%)   
 All 93 (74.4) 68 (61.8)
 Serious 4 (3.2) 4 (3.6)
Adverse events of interest  
in either treatment group, 
n (%)
  
 Arthralgia 11 (8.8) 7 (6.4)
 Pain in extremity 9 (7.2) 4 (3.6)
 Cough 5 (4.0) 5 (4.5)
 Back pain 5 (4.0) 3 (2.7)
 Osteoarthritis 2 (1.6) 3 (2.7)
 Headache 4 (3.2) 3 (2.7)
Adverse events of fracture,a 
n (%)
1 (0.8) 1 (0.9)
N = number of participants who received at least 1 dose of investi-
gational product during the corresponding treatment period (safety 
analysis population); n = number of participants reporting at least 1 
adverse event during the corresponding period.
Includes only treatment-emergent adverse events that started on or 
before the end of the corresponding treatment period.
aReported fractures were classified as osteoporotic and nonvertebral.
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participants who lost BMD in year 2 with alendronate, 
the majority remained above their pretreatment base-
line value. Those with larger BMD increases in year 
1 often showed greater BMD losses in year 2, with 
other participant characteristics not related to the re-
sponse in year 2. These data highlight the need for oral 
bisphosphonate therapy following denosumab cessation 
and BMD monitoring of patients transitioning from 
denosumab to bisphosphonates.
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